Prophylaxis of catheter-related deep vein thrombosis in cancer patients with low-dose warfarin, low molecular weight heparin, or control: A randomized, controlled, phase III study

Cancer Chemotherapy and Pharmacology

Volumn 72, Issue 1, 2013, Pages 65-73

  Lavau Denes, Sandrine ^a   Lacroix, P ^a   Maubon, A ^a   Preux, P M ^a,b   Genet, D ^a   Venat Bouvet L ^a   Labourey, J L ^a   Martin, J ^a   Slaouti, P ^a   Tubiana Mathieu, N ^a  

^a LIMOGES UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY OF LIMOGES   (France)

Author keywords

Cancer; Catheter related thromboembolism; LMWH; Prophylaxis

Indexed keywords

DALTEPARIN; ENOXAPARIN; NADROPARIN; WARFARIN;

ADULT; ADVANCED CANCER; ADVERSE OUTCOME; AGED; ARTICLE; CATHETER THROMBOSIS; CENTRAL VENOUS CATHETER; CLINICAL ASSESSMENT; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DOPPLER ECHOGRAPHY; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; EPISTAXIS; EXTRAVASATION; FEMALE; HEMATOMA; HIGH RISK PATIENT; HUMAN; KIDNEY FAILURE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PARTIAL THROMBOPLASTIN TIME; PHASE 3 CLINICAL TRIAL; PHLEBOGRAPHY; PNEUMOTHORAX; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOSIS PREVENTION; TREATMENT REFUSAL; TUMOR INVASION;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ANTINEOPLASTIC AGENTS; CENTRAL VENOUS CATHETERS; FEMALE; FRANCE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INCIDENCE; INTENTION TO TREAT ANALYSIS; LOST TO FOLLOW-UP; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NEOPLASMS; SEVERITY OF ILLNESS INDEX; UPPER EXTREMITY DEEP VEIN THROMBOSIS; VENOUS THROMBOSIS; WARFARIN; YOUNG ADULT;

EID: 84879798864     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2169-y     Document Type: Article

References (35)

1. Kirkpatrick A, Rathbun S, Whitsett T, Raskob G (2007) Prevention of central venous catheter-associated thrombosis: a meta-analysis. Am J Med 120(901):e1-e13. doi: 10.1016/j.amjmed.2007.05.010
2. Akl EA, Kamath G, Yosuico V, Kim SY, Barba M, Sperati F, Cook DJ, Schünemann HJ (2008) Thromboprophylaxis for patients with cancer and central venous catheters: a systematic review and a meta-analysis. Cancer 112:2483-2492. doi: 10.1002/cncr.23479
3. Monreal M, Raventos A, Lerma R, Ruiz J, Lafoz E, Alastrue A, Llamazares JF (1994) Pulmonary embolism in patients with upper extremity DVT associated to venous central lines-a prospective study. Thromb Haemost 72:548-550
4. De Cicco M, Matovic M, Balestreri L, Panarello G, Fantin D, Morassut S, Testa V (1997) Central venous thrombosis: an early and frequent complication in cancer patients bearing long-term silastic catheter. A prospective study. Thromb Res 86:101-113
5. Masci G, Magagnoli M, Zucali PA, Castagna L, Carnaghi C, Sarina B, Pedicini V, Fallini M, Santoro A (2003) Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: can it be safely associated with fluorouracil-based chemotherapy? J Clin Oncol 21:736-739
6. Verso M, Agnelli G (2003) Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 21:3665-3675
7. Labourey J-L, Lacroix P, Genet D, Gobeaux F, Martin J, Venat-Bouvet L, Lavau-Denes S, Maubon A, Tubiana-Mathieu N (2004) Thrombotic complications of implanted central venous access devices: prospective evaluation. Bull Cancer 91:431-436
8. Luciani A, Clement O, Halimi P, Goudot D, Portier F, Bassot V, Luciani JA, Avan P, Frija G, Bonfils P (2001) Catheter-related upper extremity deep venous thrombosis in cancer patients: a prospective study based on Doppler US. Radiology 220:655-660
9. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111:4902-4907. doi: 10.1182/blood-2007-10-116327
10. Mandalà M, Barni S, Prins M, Labianca R, Tondini C, Russo L, Milesi A, Cremonesi M, Zaccanelli M, Regonesi C, Moro C, Falanga A (2010) Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial. Ann Oncol 21:871-876. doi: 10.1093/annonc/mdr524
11. Lagro SW, Verdonck LF, Borel Rinkes IH, Dekker AW (2000) No effect of nadroparin prophylaxis in the prevention of central venous catheter (CVC)-associated thrombosis in bone marrow transplant recipients. Bone Marrow Transplant 26:1103-1106
12. Karthaus M, Kretzschmar A, Kröning H, Biakhov M, Irwin D, Marschner N, Slabber C, Fountzilas G, Garin A, Abecasis NGF, Baronius W, Steger GG, Südhoff T, Giorgetti C, Reichardt P (2006) Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. Ann Oncol 17:289-296. doi: 10.1093/annonc/mdj059
13. Verso M, Agnelli G, Bertoglio S, Di Somma FC, Paoletti F, Ageno W, Bazzan M, Parise P, Quintavalla R, Naglieri E, Santoro A, Imberti D, Sorarù M, Mosca S (2005) Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol 23:4057-4062. doi: 10.1200/JCO.2005.06.084
14. Heaton DC, Han DY, Inder A (2002) Minidose (1 mg) warfarin as prophylaxis for central vein catheter thrombosis. Int Med J 32:84-88
15. Couban S, Goodyear M, Burnell M, Dolan S, Wasi P, Barnes D, Macleod D, Burton E, Andreou P, Anderson DR (2005) Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol 23:4063-4069. doi: 10.1200/JCO.2005.10.192
16. Young AM, Billingham LJ, Begum G, Kerr DJ, Hughes AI, Rea DW, Shepherd S, Stanley A, Sweeney A, Wilde J, Wheatley K (2009) Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial. Lancet 373:567-574. doi: 10.1016/S0140-6736(09)60205-1
17. Bern MM, Lokich JJ, Wallach SR, Bothe A Jr, Benotti PN, Arkin CF, Greco FA, Huberman M, Moore C (1990) Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med 112:423-428
18. Levine M, Hirsh J, Gent M, Arnold A, Warr D, Falanga A, Samosh M, Bramwell V, Pritchard KI, Stewart D (1994) Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 343:886-889
19. Monreal M, Alastrue A, Rull M, Mira X, Muxart J, Rosell R, Abad A (1996) Upper extremity deep venous thrombosis in cancer patients with venous access devices-prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost 75:251-253
20. Agnelli G, Gussoni G, Bianchini C, Verso M, Mandalà M, Cavanna L, Barni S, Labianca R, Buzzi F, Scambia G, Passalacqua R, Ricci S, Gasparini G, Lorusso V, Bonizzoni E, Tonato M (2009) Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 10:943-949. doi: 10.1016/S1470-2045(09)70232-3
21. Maraveyas A, Waters J, Roy R, Fyfe D, Propper D, Lofts F, Sgouros J, Gardiner E, Wedgwood K, Ettelaie C, Bozas G (2012) Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer 48:1283-1292. doi: 10.1016/j.ejca.2011.10.017
22. Mismetti P, Mille D, Laporte S, Charlet V, Buchmüller-Cordier A, Jacquin J-P, Fournel P, Dutrey-Dupagne C, Decousus H (2003) Low-molecular-weight heparin (nadroparin) and very low doses of warfarin in the prevention of upper extremity thrombosis in cancer patients with indwelling long-term central venous catheters: a pilot randomized trial. Haematologica 88:67-73
23. Akl EA, Vasireddi SR, Gunukula S, Yosuico VED, Barba M, Sperati F, Cook D, Schünemann H (2011) Anticoagulation for patients with cancer and central venous catheters. Cochrane Database Syst Rev CD006468. doi: 10.1002/14651858.CD006468.pub4
24. Chaukiyal P, Nautiyal A, Radhakrishnan S, Singh S, Navaneethan SD (2008) Thromboprophylaxis in cancer patients with central venous catheters. A systematic review and meta-analysis. Thromb Haemost 99:38-43. doi: 10.1160/TH07-07-0446
25. De Cicco M, Matovic M, Balestreri L, Steffan A, Pacenzia R, Malafronte M, Fantin D, Bertuzzi CA, Fabiani F, Morassut S, Bidoli E, Veronesi A (2009) Early and short-term acenocumarine or dalteparin for the prevention of central vein catheter-related thrombosis in cancer patients: a randomized controlled study based on serial venographies. Ann Oncol 20:1936-1942. doi: 10.1093/annonc/mdp235
26. Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, Kakkar A, Kuderer NM, Levine MN, Liebman H, Mendelson D, Raskob G, Somerfield MR, Thodiyil P, Trent D, Francis CW (2007) American society of clinical oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25:5490-5505. doi: 10.1200/JCO.2007.14. 1283
27. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW (2008) Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133:381S-453S. doi: 10.1378/chest.08-0656
28. Debourdeau P, Kassab Chahmi D, Le Gal G, Kriegel I, Desruennes E, Douard M-C, Elalamy I, Meyer G, Mismetti P, Pavic M, Scrobohaci M-L, Lévesque H, Renaudin JM, Farge D (2009) 2008 SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: report from the working group. Ann Oncol 20:1459-1471. doi: 10.1093/annonc/mdp052
29. Simonneau G, Laporte S, Mismetti P, Derlon A, Samii K, Samama C-M, Bergman J-F (2006) A randomized study comparing the efficacy and safety of nadroparin 2,850 IU (0.3 mL) versus enoxaparin 4,000 IU (40 mg) in the prevention of venous thromboembolism after colorectal surgery for cancer. J Thromb Haemost 4:1693-1700. doi: 10.1111/j.1538-7836.2006.02083.x
30. Klerk CPW, Smorenburg SM, Otten H-M, Lensing AWA, Prins MH, Piovella F, Prandoni P, Bos MMEM, Richel DJ, Van Tienhoven G, Büller HR (2005) The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 23:2130-2135. doi: 10.1200/JCO.2005.03.134
31. Balestreri L, De Cicco M, Matovic M, Coran F, Morassut S (1995) Central venous catheter-related thrombosis in clinically asymptomatic oncologic patients: a phlebographic study. Eur J Radiol 20:108-111
32. Thaler J, Ay C, Pabinger I (2012) Venous thromboembolism in cancer patients - Risk scores and recent randomised controlled trials. Thromb Haemost 108:1042-1048. doi: 10.1160/TH12-04-0241
33. Mandala M, Clerici M, Corradino I, Vitalini C, Colombini S, Torri V, De Pascale A, Marsoni S (2012) Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the "SENDO experience". Ann Oncol 23:1416-1421. doi: 10.1093/annonc/mdr524
34. Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, Mouret P, Chaudhari U, Lawson F, Turpie AGG (2012) Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 366:601-609. doi: 10.1056/NEJMoa1108898
35. Dutia M, White RH, Wun T (2012) Risk assessment models for cancer-associated venous thromboembolism. Cancer 118:3468-3476. doi: 10.1002/cncr.26597